Status:
NOT_YET_RECRUITING
QualiTy of Life Evaluation in Patients With ChRonic ObstructIve Pulmonary Disease Who Require Tiotropium as additiOnal treatmeNt.
Lead Sponsor:
Elpen Pharmaceutical Co. Inc.
Conditions:
COPD
Eligibility:
All Genders
40-90 years
Brief Summary
Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous disease usually with a decline lung function and worsening symptoms; hence, both forced expiratory volume in 1 s (FEV1; lung fu...
Detailed Description
With the availability of numerous PROs, it is important to understand which provide a better evaluation of patients' health status and demonstrate responses to treatment. Even when PROs evaluate the s...
Eligibility Criteria
Inclusion
- Adult patients (≥40 years old) with a diagnosis of Chronic Respiratory Pulmonary Disease (COPD).
- Patients who were treated with Inhaled Corticosteroid (ICS)/LABA, LABA/LAMA with a LABA or ICS/LABA or were not receiving long-acting bronchodilators (LABA or LAMA) for COPD and required addition of tiotropium from 1 to 7 days before the start of the study.
- Patients who are able to provide informed consent and follow study procedures and requirements.
Exclusion
- According to the contraindications of the product's Summary of Product Characteristics.
- Patients receiving LAMA monotherapy prior to study entry.
Key Trial Info
Start Date :
March 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06170125
Start Date
March 1 2024
End Date
February 1 2026
Last Update
February 20 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.